Medscape Hematology-Oncology Headlines This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

ESD Curbs Adenoma Recurrence but More Adverse Events ESD Curbs Adenoma Recurrence but More Adverse Events
For large colonic adenomas, endoscopic submucosal dissection reduces the recurrence rate compared with endoscopic mucosal resection, but the adverse event rate is higher.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 20, 2023 Category: Cancer & Oncology Tags: Gastroenterology Source Type: news

New Multiple Myeloma Staging Systems Outperform the Standard New Multiple Myeloma Staging Systems Outperform the Standard
Findings from a large US cohort study show comparable accuracy, but better discrimination of patients across disease stages.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 20, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

GLP-1 RAs Associated With Reduced CRC Risk in T2DM GLP-1 RAs Associated With Reduced CRC Risk in T2DM
The effects were more profound in patients with overweight and obesity in addition to diabetes.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 19, 2023 Category: Cancer & Oncology Tags: Gastroenterology Source Type: news

FDA OKs Enfortumab Vedotin Plus Pembro for Urothelial Cancer FDA OKs Enfortumab Vedotin Plus Pembro for Urothelial Cancer
The combination is the first approved alternative to first-line chemotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 18, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

EU Conditional Approval: Gene Editor to Treat Blood Diseases EU Conditional Approval: Gene Editor to Treat Blood Diseases
The single-dose therapy involves treating and editing patient stem cells ex vivo, then reinfusing them.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 18, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Checkpoint Therapeutics Slides After US FDA Declines Cancer Therapy Approval Checkpoint Therapeutics Slides After US FDA Declines Cancer Therapy Approval
Checkpoint Therapeutics said on Monday the U.S. Food and Drug Administration had declined to approve its experimental therapy to treat a form of skin cancer following an...Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 18, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Belzutifan Approved for Advanced Renal Cell Carcinoma Belzutifan Approved for Advanced Renal Cell Carcinoma
The FDA approval makes belzutifan the first agent specifically indicated for renal cell carcinoma that has progressed after checkpoint inhibition and a VEGF-TKI.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 15, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

All In: Two Cancers, One Surgical Team Who's Not Giving Up All In: Two Cancers, One Surgical Team Who's Not Giving Up
Surgeons know not to count on miracles, but sometimes they can happen. Our cameras follow a surgical team as they work together to treat a patient with an uncertain outcome.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 15, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

This Frontline Therapy Is Better in Multiple Myeloma: Study This Frontline Therapy Is Better in Multiple Myeloma: Study
A study directly comparing real-world outcomes suggests patients with transplant-ineligible multiple myeloma do better with frontline triple therapy with daratumumab vs bortezomib.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 14, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Survival-Toxicity Trade-off With T-DM1 in HER+ Breast Cancer Survival-Toxicity Trade-off With T-DM1 in HER+ Breast Cancer
Older patients with advanced HER2+ breast cancer do not experience a survival benefit with trastuzumab emtansine vs standard-of-care combination therapy, although toxicity is improved, a trial shows.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 14, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Bluebird Signs Pact With Insurer for Sickle Cell Gene Therapy Bluebird Signs Pact With Insurer for Sickle Cell Gene Therapy
Bluebird bio said on Thursday a large insurer had agreed to cover its newly approved sickle cell disease gene therapy, easing some investor worries about resistance from...Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 14, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

What if a Single GLP-1 Shot Could Last for Months? What if a Single GLP-1 Shot Could Last for Months?
New hydrogel technology could reduce GLP-1 injections from daily or weekly to three times a year.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 14, 2023 Category: Cancer & Oncology Tags: Diabetes & Endocrinology Source Type: news

Less Is More for Axillary Surgery in Early Breast Cancer Less Is More for Axillary Surgery in Early Breast Cancer
Women with early breast cancer can safely undergo less extensive axillary surgery because it has no impact on recurrence or mortality rates but reduces the risk for lymphedema, a meta-analysis shows.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

No Benefit to Salvage Transplant in R/R Multiple Myeloma No Benefit to Salvage Transplant in R/R Multiple Myeloma
Long-term follow-up shows no progression-free or overall survival advantage among patients who received salvage transplant vs continuous lenalidomide plus dexamethasone.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

' Baby Tam' Effective, Tolerable for Breast Cancer Prevention'Baby Tam' Effective, Tolerable for Breast Cancer Prevention
Lower-dose tamoxifen aims to reduce those side effects, but there remains some uncertainty about the minimum dose required to maintain efficacy.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news